Annexin Pharmaceuticals AB and CDMO Biovian Oy released the First-In-Class ANXV drug candidate for clinical trials. Following a clinical study in healthy subjects, clinical trials with the drug will target retinal vein occlusion, a condition …
The therapeutic possibilities of cell and gene therapy are very appealing. The possibility to use a Viral Vector to carry the therapeutic gene into the target cells or to initiate cell transduction holds the potential …
